DAFNA Capital Management LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), DAFNA Capital Management LLC reported 71 stock positions worth $434.7 million. Its top holding was SS SPDR S&P Biotech ETF (XBI) at 9.4% of the portfolio, followed by Stereotaxis (STXS, 8.2%) and Cytokinetics (CYTK, 6.4%). Compared with Q4 2023, it opened 10 new positions, sold out of 14, added to 12 and reduced 30. The biggest buy was a new position in Perspective Therapeutics (CATX) and the biggest sale an exit from Karuna Therapeutics (KRTX).
- Most Recent 13F
- Q2 2026
- Location
- LOS ANGELES, CA
- CIK
- 0001389933
- Portfolio Value
- $434.7M (Q1 2024)
- SEC Filing
- 0001389932-24-000012 ↗ filed May 15, 2024
Holdings Value
Holdings 71 stocks · $434.7M
| XBI SS SPDR S&P Biotech ETF | 9.41% | 431,215 | $40.9M | Reduce -10.9% |
| STXS Stereotaxis Inc. | 8.21% | 13,680,554 | $35.7M | No change |
| CYTK Cytokinetics Inc. | 6.42% | 398,100 | $27.9M | Reduce -0.5% |
| IDYA Ideaya Biosciences Inc. | 4.51% | 446,341 | $19.6M | Reduce -13.6% |
| MRUS Merus NV | 3.93% | 378,995 | $17.1M | Reduce -16.7% |
| RVMD Revolution Medicines Inc. | 3.80% | 511,894 | $16.5M | No change |
| VKTX Viking Therapeutics Inc. | 3.66% | 194,117 | $15.9M | Reduce -21.8% |
| SNDX Syndax Pharmaceuticals Inc. | 3.61% | 659,574 | $15.7M | Reduce -11.2% |
| IBB iShares Biotechnology ETF | 3.24% | 102,500 | $14.1M | No change |
| ASND Ascendis Pharma A/S | 3.22% | 92,472 | $14.0M | Reduce -25.1% |
| XENE Xenon Pharmaceuticals Inc. | 2.71% | 273,739 | $11.8M | Reduce -1.1% |
| DAWN Day One Biopharmaceuticals I | 2.53% | 666,463 | $11.0M | Reduce -2.9% |
| BPMC Blueprint Medicines Corp. | 2.33% | 106,763 | $10.1M | Reduce -3.7% |
| NBIX Neurocrine Biosciences Inc. | 2.27% | 71,615 | $9.9M | Reduce -1.4% |
| KALV Kalvista Pharmaceuticals Inc. | 2.20% | 806,973 | $9.6M | Add +34.3% |
| TNDM Tandem Diabetes Care Inc. | 2.10% | 258,208 | $9.1M | Add +17.0% |
| DXCM Dexcom Inc. | 2.09% | 65,552 | $9.1M | Reduce -3.0% |
| KURA Kura Oncology Inc. | 2.02% | 412,663 | $8.8M | Reduce -16.2% |
| ATRC Atricure Inc. | 1.90% | 271,029 | $8.2M | Add +115.9% |
| MORF Morphic Holding Inc. | 1.88% | 231,748 | $8.2M | No change |
| AXGN Axogen Inc. | 1.74% | 935,894 | $7.6M | No change |
| BHVN Biohaven Ltd. | 1.49% | 118,730 | $6.5M | Reduce -29.6% |
| TSVT 2SEVENTY Bio Inc. | 1.48% | 1,204,051 | $6.4M | Reduce -16.8% |
| EWTX Edgewise Therapeutics Inc. | 1.28% | 306,197 | $5.6M | Reduce -31.9% |
| ALEC Alector Inc. | 1.26% | 912,928 | $5.5M | Add +49.7% |
| IPSC Century Therapeutics Inc. | 1.26% | 1,307,407 | $5.5M | No change |
| LRMR Larimar Therapeutics Inc. | 1.15% | 656,373 | $5.0M | Add +102.7% |
| KROS Keros Therapeutics Inc. | 1.03% | 67,754 | $4.5M | Reduce -8.9% |
| RCUS Arcus Biosciences Inc. | 1.01% | 231,717 | $4.4M | Reduce -0.4% |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 0.96% | 130,175 | $4.2M | No change |
| CATX Perspective Therapeutics Inc. | 0.85% | 3,103,644 | $3.7M | New |
| BCRX Biocryst Pharmaceuticals Inc. | 0.83% | 709,500 | $3.6M | No change |
| ATXS Astria Therapeutics Inc. | 0.72% | 223,265 | $3.1M | Reduce -50.3% |
| RGLS Regulus Therapeutics Inc. | 0.71% | 1,070,548 | $3.1M | Reduce -3.6% |
| BCYC Bicycle Therapeutics PLC-ADR | 0.70% | 122,200 | $3.0M | No change |
| ARAY Accuray Inc. | 0.69% | 1,222,358 | $3.0M | No change |
| PODD Insulet Corp. | 0.63% | 15,900 | $2.7M | New |
| PRCT Procept Biorobotics Corp. | 0.63% | 54,995 | $2.7M | Reduce -13.1% |
| MDWD Mediwound Ltd. | 0.62% | 188,753 | $2.7M | Reduce -26.7% |
| SPRY Ars Pharmaceuticals Inc. | 0.56% | 239,194 | $2.4M | Reduce -23.1% |
| AQST Aquestive Therapeutics Inc. | 0.49% | 500,000 | $2.1M | New |
| PRQR Proqr Therapeutics NV | 0.48% | 905,582 | $2.1M | Reduce -3.7% |
| CMPS Compass Pathways PLC | 0.47% | 243,210 | $2.0M | Add +26.0% |
| LCTX Lineage Cell Therapeutics Inc. | 0.47% | 1,366,308 | $2.0M | New |
| STOK Stoke Therapeutics Inc. | 0.45% | 145,000 | $2.0M | New |
| STRO Sutro Biopharma Inc. Com SHS | 0.43% | 334,079 | $1.9M | Add +18.0% |
| INGN Inogen Inc. | 0.39% | 208,790 | $1.7M | Add +1291.9% |
| GOSS Gossamer Bio Inc. | 0.38% | 1,409,262 | $1.7M | Reduce -4.5% |
| BWAY Brainsway Ltd.-ADR | 0.36% | 297,655 | $1.6M | Reduce -3.5% |
| BNTX Biontech SE-ADR | 0.36% | 17,000 | $1.6M | New |
| IMTX Immatics NV | 0.35% | 145,000 | $1.5M | Add +38.1% |
| STIM Neuronetics Inc. | 0.34% | 313,717 | $1.5M | No change |
| ACET Adicet Bio Inc. | 0.32% | 600,000 | $1.4M | New |
| AUTL Autolus Therapeutics PLC | 0.32% | 216,667 | $1.4M | Add +13.4% |
| SLRN Acelyrin Inc. | 0.31% | 202,587 | $1.4M | Reduce -45.4% |
| ITOS Iteos Therapeutics Inc. | 0.31% | 98,560 | $1.3M | No change |
| MLYS Mineralys Therapeutics Inc. | 0.27% | 90,000 | $1.2M | Add +492.1% |
| CGEN Compugen Ltd. | 0.26% | 430,202 | $1.1M | Add +109.7% |
| IMVT Immunovant Inc. | 0.22% | 29,416 | $950K | Reduce -27.8% |
| ACRV Acrivon Therapeutics Inc. | 0.22% | 131,351 | $939K | No change |
| APRE Aprea Therapeutics Inc. | 0.21% | 137,174 | $918K | New |
| PYPD Polypid Ltd. | 0.20% | 185,446 | $853K | New |
| SYRS Syros Pharmaceuticals Inc. | 0.17% | 135,850 | $727K | Reduce -36.8% |
| ADAPY Adaptimmune Therapeutics-ADR | 0.12% | 341,064 | $539K | Reduce -2.9% |
| MASI Masimo Corp. | 0.10% | 3,000 | $441K | No change |
| NVRO Nevro LLC filed as NEVRO CORP | 0.09% | 28,000 | $404K | No change |
| KPTI Karyopharm Therapeutics Inc. | 0.07% | 192,678 | $291K | No change |
| VIGL Vigil Neuroscience Inc. | 0.06% | 71,815 | $245K | No change |
| CMPX Compass Therapeutics Inc. | 0.05% | 116,882 | $231K | No change |
| SPRO Spero Therapeutics Inc. | 0.05% | 125,000 | $215K | No change |
| ANRO Alto Neuroscience Inc. | 0.04% | 10,000 | $154K | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $4.6M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| ASCENDIS PHARMA A/S (ASND 2.25 04/01/28) | NOTE 2.250% 4/0 · principal | 4,000,000 | $4.6M | No change |
Total filed on the 13F, all lines: $439.3M.
Portfolio Sells Q4 2023 → Q1 2024
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −3.69 |
| CYTK Cytokinetics Inc. | Reduce -0.5% | 6.42% | −1.66 |
| IMGN Immunogen Inc. | Sold out | 0.00% | −1.39 |
| SAGE Sage Therapeutics Inc. | Sold out | 0.00% | −1.28 |
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −1.27 |
| XBI SS SPDR S&P Biotech ETF | Reduce -10.9% | 9.41% | −1.05 |
| ASND Ascendis Pharma A/S | Reduce -25.1% | 3.22% | −0.55 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.44 |
| MREO Mereo Biopharma Group PL-ADR | Sold out | 0.00% | −0.44 |
| SPRB Spruce Biosciences Inc. | Sold out | 0.00% | −0.39 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -1.1% | 2.71% | −0.37 |
| SLRN Acelyrin Inc. | Reduce -45.4% | 0.31% | −0.36 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −0.35 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −0.33 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −0.31 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -11.2% | 3.61% | −0.27 |
| BHVN Biohaven Ltd. | Reduce -29.6% | 1.49% | −0.25 |
| SYRS Syros Pharmaceuticals Inc. | Reduce -36.8% | 0.17% | −0.24 |
| IMVT Immunovant Inc. | Reduce -27.8% | 0.22% | −0.20 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.16 |
| BPMC Blueprint Medicines Corp. | Reduce -3.7% | 2.33% | −0.14 |
| BWAY Brainsway Ltd.-ADR | Reduce -3.5% | 0.36% | −0.12 |
| ATXS Astria Therapeutics Inc. | Reduce -50.3% | 0.72% | −0.11 |
| RCUS Arcus Biosciences Inc. | Reduce -0.4% | 1.01% | −0.07 |
| ELEV Elevation Oncology Inc. | Sold out | 0.00% | −0.06 |
| VTGN Vistagen Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| NBIX Neurocrine Biosciences Inc. | Reduce -1.4% | 2.27% | −0.04 |
| KNTE Kinnate Biopharma Inc. | Sold out | 0.00% | −0.03 |
| PRCT Procept Biorobotics Corp. | Reduce -13.1% | 0.63% | −0.02 |
| MDWD Mediwound Ltd. | Reduce -26.7% | 0.62% | −0.02 |
| TSVT 2SEVENTY Bio Inc. | Reduce -16.8% | 1.48% | −0.01 |
| PRQR Proqr Therapeutics NV | Reduce -3.7% | 0.48% | +0.03 |
| ADAPY Adaptimmune Therapeutics-ADR | Reduce -2.9% | 0.12% | +0.06 |
| GOSS Gossamer Bio Inc. | Reduce -4.5% | 0.38% | +0.06 |
| IDYA Ideaya Biosciences Inc. | Reduce -13.6% | 4.51% | +0.06 |
| DXCM Dexcom Inc. | Reduce -3.0% | 2.09% | +0.06 |
| EWTX Edgewise Therapeutics Inc. | Reduce -31.9% | 1.28% | +0.10 |
| DAWN Day One Biopharmaceuticals I | Reduce -2.9% | 2.53% | +0.11 |
| SPRY Ars Pharmaceuticals Inc. | Reduce -23.1% | 0.56% | +0.15 |
| KURA Kura Oncology Inc. | Reduce -16.2% | 2.02% | +0.31 |
| KROS Keros Therapeutics Inc. | Reduce -8.9% | 1.03% | +0.32 |
| RGLS Regulus Therapeutics Inc. | Reduce -3.6% | 0.71% | +0.37 |
| MRUS Merus NV | Reduce -16.7% | 3.93% | +0.90 |
| VKTX Viking Therapeutics Inc. | Reduce -21.8% | 3.66% | +2.54 |
Portfolio Buys Q4 2023 → Q1 2024
| CATX Perspective Therapeutics Inc. | New | 0.85% | +0.85 |
| ATRC Atricure Inc. | Add +115.9% | 1.90% | +0.81 |
| LRMR Larimar Therapeutics Inc. | Add +102.7% | 1.15% | +0.79 |
| PODD Insulet Corp. | New | 0.63% | +0.63 |
| TNDM Tandem Diabetes Care Inc. | Add +17.0% | 2.10% | +0.52 |
| AQST Aquestive Therapeutics Inc. | New | 0.49% | +0.49 |
| LCTX Lineage Cell Therapeutics Inc. | New | 0.47% | +0.47 |
| STOK Stoke Therapeutics Inc. | New | 0.45% | +0.45 |
| KALV Kalvista Pharmaceuticals Inc. | Add +34.3% | 2.20% | +0.42 |
| INGN Inogen Inc. | Add +1291.9% | 0.39% | +0.37 |
| BNTX Biontech SE-ADR | New | 0.36% | +0.36 |
| ACET Adicet Bio Inc. | New | 0.32% | +0.32 |
| MLYS Mineralys Therapeutics Inc. | Add +492.1% | 0.27% | +0.24 |
| APRE Aprea Therapeutics Inc. | New | 0.21% | +0.21 |
| PYPD Polypid Ltd. | New | 0.20% | +0.20 |
| CGEN Compugen Ltd. | Add +109.7% | 0.26% | +0.16 |
| STRO Sutro Biopharma Inc. Com SHS | Add +18.0% | 0.43% | +0.14 |
| ALEC Alector Inc. | Add +49.7% | 1.26% | +0.09 |
| IMTX Immatics NV | Add +38.1% | 0.35% | +0.08 |
| CMPS Compass Pathways PLC | Add +26.0% | 0.47% | +0.06 |
| ANRO Alto Neuroscience Inc. | New | 0.04% | +0.04 |
| AUTL Autolus Therapeutics PLC | Add +13.4% | 0.32% | +0.02 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 88 | $524.4M | RVMD, XBI, CMPS, STXS, NKTR |
| Q1 2026 | 82 | $433.7M | RVMD, XBI, STXS, DAWN, ATRC |
| Q4 2025 | 76 | $425.1M | RVMD, XBI, STXS, ATRC, CYTK |
| Q3 2025 | 74 | $399.3M | STXS, XBI, RVMD, CYTK, ATRC |
| Q2 2025 | 75 | $357.2M | XBI, STXS, RVMD, BPMC, MRUS |
| Q1 2025 | 82 | $348.0M | XBI, STXS, RVMD, MRUS, ATRC |
| Q4 2024 | 81 | $389.0M | XBI, STXS, RVMD, ATRC, MRUS |
| Q3 2024 | 83 | $418.6M | XBI, STXS, RVMD, CYTK, MRUS |
| Q2 2024 | 82 | $414.1M | XBI, STXS, MRUS, CYTK, RVMD |
| Q1 2024 | 71 | $434.7M | XBI, STXS, CYTK, IDYA, MRUS |